Cav2.3 Antagonists Resolving Off-Target Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current Cav2.3 antagonists, such as SNX-482, exhibit off-target effects and toxicity, making them unsuitable for therapeutic use in treating neurodegenerative diseases like Parkinson's disease.
Innovation Solution
Development of novel compounds with the formula (I) or their pharmaceutically acceptable salts, which selectively antagonize Cav2.3 channels without significant off-target effects, thereby providing a neuroprotective treatment for Parkinson's disease and other Cav2.3-mediated disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing Cav2.3 antagonists like SNX-482 are used, then Cav2.3 channel blocking activity is achieved, but off-target effects and toxicity occur
Solution Approach 1:
The patent modifies the chemical structure of Cav2.3 antagonists by changing molecular parameters (introducing specific substituents at defined positions in the formula I structure) to alter binding characteristics. This results in compounds that maintain Cav2.3 blocking activity while reducing affinity for off-target channels, thereby resolving the contradiction between effective channel blocking and harmful off-target effects
Solution Approach 2:
The patent applies local quality by introducing specific functional groups and substituents at particular locations within the molecular structure (R1-R12 positions in formula I). These localized structural modifications create regions of high specificity for Cav2.3 while minimizing interactions with other channel types, achieving selective blocking without widespread toxicity
2Reliability
If Cav2.3 channels are blocked to treat Parkinson's disease, then neurodegeneration is reduced, but neurotoxicity may increase
Solution Approach 1:
The patent employs parameter changes by optimizing the pharmacological profile of Cav2.3 antagonists through structural modification. The compounds exhibit enhanced selectivity for Cav2.3 over other neuronal channels, ensuring neuroprotective benefits through selective blocking while avoiding the neurotoxicity that would result from non-selective channel inhibition
Solution Approach 2:
The patent converts the potential harm of channel blocking (neurotoxicity) into a benefit by using selectively active compounds that target only Cav2.3 channels. The structured approach ensures that blocking activity is concentrated on the pathogenic Cav2.3 channels in Parkinson's disease while sparing other neuronal channels, thus transforming a potentially toxic mechanism into a safe therapeutic approach
Data Source
AI summary
Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof: (I) wherein Ring A, R1, R2, R3, R4, Y1, Y2, Y3, Y4, a, t, u, and L are as defined herein. The compounds are antagonists of the resistant (R-type) voltage-gated calcium ion channel Cav 2.3. Also disclosed are pharmaceutical compositions comprising the compounds; and the compounds for use in the treatment of diseases modulated Cav 2.3, including neurodegenerative conditions such as Parkinson's disease, focal, drug-resistant forms of epilepsy, and other neurological disorders such as developmental and epileptic encephalopathies and Fragile X syndrome.